Drug intelligence / Profile preview

TC-13-183

Development stage: Unknown
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intraperitoneal

Overview

TC-13-183 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Chongqing Precision Biotechnology. It is designed to target carcinoembryonic antigen (CEA) and is developed using the company's proprietary ToughCAR® platform, which utilizes a metabolically optimized rapid manufacturing process. This platform allows for faster preparation and a therapeutic dose that is approximately one-tenth of conventional CAR-T therapies, enhancing CAR-T cell function and suitability for solid tumors. TC-13-183 is administered via local intraperitoneal injection to treat CEA-positive advanced peritoneal metastatic colorectal cancer.

Other names: TC-13-183细胞制剂

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on TC-13-183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC-13-183.